Patents by Inventor Sharmistha Das
Sharmistha Das has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240013867Abstract: The invention relates to a method for a computer device, for detecting an optimal candidate compound based on a plurality of samples comprising a cell line and one or more biomarkers, and a plate map configuration, wherein the plate map configuration is providing locations of samples comprising cell lines exposed to one or more biomarkers and different concentrations of a candidate compound forming at least one concentration gradient, the candidate compound being comprised in a plurality of candidate compounds, said method comprising generating (310) phenotypic profiles of each concentration gradient of each of the plurality of candidate compounds at a plurality of successive points in time to form a plurality of compound profiles, wherein generating phenotypic profiles comprises the steps obtaining (312) image data depicting each sample comprised in the concentration gradient, generating (314) a class-label and a class for each cell of the samples based on the image data, detecting (320) the optimal candidatType: ApplicationFiled: March 10, 2023Publication date: January 11, 2024Inventors: Emmanuel Israel Fuentes, Gopal Biligeri Avinash, Robert John Graves, Abhijit Vijay Thatte, Afek Kodesh, Jeffery Caron, Sharmistha Das
-
Patent number: 11636924Abstract: The invention relates to a method for a computer device, for detecting an optimal candidate compound based on a plurality of samples comprising a cell line and one or more biomarkers, and a plate map configuration, wherein the plate map configuration is providing locations of samples comprising cell lines exposed to one or more biomarkers and different concentrations of a candidate compound forming at least one concentration gradient, the candidate compound being comprised in a plurality of candidate compounds, said method comprising generating (310) phenotypic profiles of each concentration gradient of each of the plurality of candidate compounds at a plurality of successive points in time to form a plurality of compound profiles, wherein generating phenotypic profiles comprises the steps obtaining (312) image data depicting each sample comprised in the concentration gradient, generating (314) a class-label and a class for each cell of the samples based on the image data, detecting (320) the optimal candidatType: GrantFiled: October 2, 2017Date of Patent: April 25, 2023Assignee: Molecular Devices, LLCInventors: Emmanuel Israel Fuentes, Gopal Biligeri Avinash, Robert John Graves, Abhijit Vijay Thatte, Afek Kodesh, Jeffery Caron, Sharmistha Das
-
Publication number: 20210005287Abstract: The invention relates to a method for a computer device, for detecting an optimal candidate compound based on a plurality of samples comprising a cell line and one or more biomarkers, and a plate map configuration, wherein the plate map configuration is providing locations of samples comprising cell lines exposed to one or more biomarkers and different concentrations of a candidate compound forming at least one concentration gradient, the candidate compound being comprised in a plurality of candidate compounds, said method comprising generating (310) phenotypic profiles of each concentration gradient of each of the plurality of candidate compounds at a plurality of successive points in time to form a plurality of compound profiles, wherein generating phenotypic profiles comprises the steps obtaining (312) image data depicting each sample comprised in the concentration gradient, generating (314) a class-label and a class for each cell of the samples based on the image data, detecting (320) the optimal candidatType: ApplicationFiled: October 2, 2017Publication date: January 7, 2021Inventors: Emmanuel Israel Fuentes, Gopal Biligeri Avinash, Robert John Graves, Abhijit Vijay Thatte, Afek Kodesh, Jeffery Caron, Sharmistha Das
-
Patent number: 8700597Abstract: Using natural language-like user inputs to provide statistics on a subset of data is described. In one embodiment, a user input that includes at least one word or phrase representing a rule is received. The rule includes an identification of a subset of data and a statistical expression to be performed on the subset of data. The subset of data includes at least part of the data elements of a data set. Each data element includes information on an individual or group. Instructions are provided for translating the rule into an executable format. The executable format includes a translated identification of the subset and a translated statistical expression. The subset of the data is accessed using the translated identification of the subset. The translated statistical expression is executed to obtain statistics on data elements of the subset of data. The statistics on the data elements are provided.Type: GrantFiled: August 6, 2008Date of Patent: April 15, 2014Assignee: Equifax, Inc.Inventors: Sandeep Gupta, James R. Reid, Matthew P. Welsh, Shannon M. Cothran, Sharmistha Das
-
Patent number: 8124581Abstract: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to all members of the NRIF3 family. Two other death domains (DD2 and DD3) were also found to have effective breast cancer killing activities. Mechanistic studies showed that DD1-induced apoptosis occurred through a novel caspase-2 mediated pathway that involved mitochondria membrane permeabilization but did not require other caspases. Interestingly, cytotoxicity of NRIF3 related molecules was cell-type specific, as they selectively killed breast cancer or related cells but not other examined cells of different origins, suggesting the presence in breast cancer cells of a specific death switch that can be selectively triggered by NRIF3 and related molecules.Type: GrantFiled: June 4, 2010Date of Patent: February 28, 2012Assignee: New York UniversityInventors: Li Dangsheng, Sharmistha Das, Herbert Samuels
-
Publication number: 20100317594Abstract: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to all members of the NRIF3 family. Two other death domains (DD2 and DD3) were also found to have effective breast cancer killing activities. Mechanistic studies showed that DD1-induced apoptosis occurred through a novel caspase-2 mediated pathway that involved mitochondria membrane permeabilization but did not require other caspases. Interestingly, cytotoxicity of NRIF3 related molecules was cell-type specific, as they selectively killed breast cancer or related cells but not other examined cells of different origins, suggesting the presence in breast cancer cells of a specific death switch that can be selectively triggered by NRIF3 and related molecules.Type: ApplicationFiled: June 4, 2010Publication date: December 16, 2010Applicant: New York UniversityInventors: Li Dangsheng, Sharmistha Das, Herbert Samuels
-
Patent number: 7772202Abstract: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to all members of the NRIF3 family. Two other death domains (DD2 and DD3) were also found to have effective breast cancer killing activities. Mechanistic studies showed that DD1-induced apoptosis occurred through a novel caspase-2 mediated pathway that involved mitochondria membrane permeabilization but did not require other caspases. Interestingly, cytotoxicity of NRIF3 related molecules was cell-type specific, as they selectively killed breast cancer or related cells but not other examined cells of different origins, suggesting the presence in breast cancer cells of a specific death switch that can be selectively triggered by NRIF3 and related molecules.Type: GrantFiled: August 7, 2007Date of Patent: August 10, 2010Assignee: New York UniversityInventors: Li Dangsheng, Sharmistha Das, Herbert Samuels
-
Publication number: 20090044096Abstract: Using natural language-like user inputs to provide statistics on a subset of data is described. In one embodiment, a user input that includes at least one word or phrase representing a rule is received. The rule includes an identification of a subset of data and a statistical expression to be performed on the subset of data. The subset of data includes at least part of the data elements of a data set. Each data element includes information on an individual or group. Instructions are provided for translating the rule into an executable format. The executable format includes a translated identification of the subset and a translated statistical expression. The subset of the data is accessed using the translated identification of the subset. The translated statistical expression is executed to obtain statistics on data elements of the subset of data. The statistics on the data elements are provided.Type: ApplicationFiled: August 6, 2008Publication date: February 12, 2009Inventors: Sandeep Gupta, James R. Reid, Matthew P. Welsh, Shannon M. Cothran, Sharmistha Das
-
Publication number: 20080182794Abstract: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to all members of the NRIF3 family. Two other death domains (DD2 and DD3) were also found to have effective breast cancer killing activities. Mechanistic studies showed that DD1-induced apoptosis occurred through a novel caspase-2 mediated pathway that involved mitochondria membrane permeabilization but did not require other caspases. Interestingly, cytotoxicity of NRIF3 related molecules was cell-type specific, as they selectively killed breast cancer or related cells but not other examined cells of different origins, suggesting the presence in breast cancer cells of a specific death switch that can be selectively triggered by NRIF3 and related molecules.Type: ApplicationFiled: August 7, 2007Publication date: July 31, 2008Applicant: NEW YORK UNIVERSITYInventors: Li Dangsheng, Sharmistha Das, Herbert Samuels
-
Publication number: 20050272651Abstract: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to all members of the NRIF3 family. Two other death domains (DD2 and DD3) were also found to have effective breast cancer killing activities. Mechanistic studies showed that DD1-induced apoptosis occurred through a novel caspase-2 mediated pathway that involved mitochondria membrane permeabilization but did not require other caspases. Interestingly, cytotoxicity of NRIF3 related molecules was cell-type specific, as they selectively killed breast cancer or related cells but not other examined cells of different origins, suggesting the presence in breast cancer cells of a specific death switch that can be selectively triggered by NRIF3 and related molecules.Type: ApplicationFiled: February 23, 2005Publication date: December 8, 2005Applicant: New York UniversityInventors: Li Dangsheng, Sharmistha Das, Herbert Samuels
-
Patent number: 6950511Abstract: A plurality of Goertzel filters whose operating frequencies are distributed across the voice baseband are used to detect voice and control tones in a signal. Filters operating at frequencies of control tones and detecting that most of the signal energy occurs at those frequencies indicates presence of the control tones. At least three of the filters detecting that about 10% to 20% of the signal energy occurs at each of their operating frequencies indicate presence of voice. The total energy detected in the signal being below a noise threshold indicates presence of noise or silence.Type: GrantFiled: November 13, 2003Date of Patent: September 27, 2005Assignee: Avaya Technology Corp.Inventors: Sharmistha Das, Matthew McShea
-
Publication number: 20050105716Abstract: A plurality of Goertzel filters whose operating frequencies are distributed across the voice baseband are used to detect voice and control tones in a signal. Filters operating at frequencies of control tones and detecting that most of the signal energy occurs at those frequencies indicates presence of the control tones. At least three of the filters detecting that about 10% to 20% of the signal energy occurs at each of their operating frequencies indicate presence of voice. The total energy detected in the signal being below a noise threshold indicates presence of noise or silence.Type: ApplicationFiled: November 13, 2003Publication date: May 19, 2005Inventors: Sharmistha Das, Matthew McShea